Human infection by orthopoxvirus

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:438279B04B03B08.0
Who is this for?
Show terms as
8Active trials8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Human infection by orthopoxvirus refers to diseases caused by viruses in the orthopoxvirus family. This group includes several well-known infections: smallpox (caused by variola virus), monkeypox (now called mpox, caused by monkeypox virus), cowpox, and vaccinia virus infections. Smallpox was one of the deadliest diseases in human history but was officially eradicated in 1980 through a global vaccination campaign. However, other orthopoxvirus infections still occur and are considered rare diseases. These viruses typically affect the skin and cause a characteristic rash that progresses through stages — starting as flat spots, then raised bumps, fluid-filled blisters, and finally scabs that fall off. Patients often experience fever, headache, muscle aches, swollen lymph nodes, and extreme tiredness before the rash appears. The severity varies widely depending on which specific virus is involved, with smallpox being the most dangerous and cowpox generally being milder. Treatment is mainly supportive, meaning doctors focus on managing symptoms and preventing complications. Antiviral medications such as tecovirimat (TPOXX) have been approved for use in certain orthopoxvirus infections. Vaccination with modified vaccinia Ankara (MVA, marketed as Jynneos) can help prevent infection or reduce severity if given shortly after exposure. People with weakened immune systems, young children, and pregnant women are at higher risk for severe disease.

Key symptoms:

FeverSkin rash that progresses from flat spots to blisters to scabsHeadacheMuscle aches and body painSwollen lymph nodesExtreme tiredness and fatigueChillsBack painSore throatPainful skin lesionsLesions in the mouth or on mucous membranesDifficulty swallowingEye inflammation or painSecondary skin infections

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jan 2026Prospective Follow-up After MVA-BN Booster Vaccination

Institute of Tropical Medicine, Belgium

TrialNOT YET RECRUITING
Dec 2025Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo

Shanghai Institute Of Biological Products — PHASE2

TrialNOT YET RECRUITING
Oct 2025Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Bavarian Nordic — PHASE2

TrialRECRUITING
Aug 2025An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC

Institute of Tropical Medicine, Belgium — PHASE2

TrialRECRUITING
May 2025Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Jean-Pierre Van geertruyden — PHASE3

TrialRECRUITING
May 2025Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

Assistance Publique - Hôpitaux de Paris

TrialRECRUITING
Jan 2025A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

Shanghai Institute Of Biological Products — PHASE1

TrialRECRUITING
Oct 2024Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Bavarian Nordic — PHASE2

TrialACTIVE NOT RECRUITING
Oct 2024Observational Mondkeypox Pregnancy Cohort

Robert Colebunders

TrialNOT YET RECRUITING
Jun 2024Evaluating the Human Immune Response to the JYNNEOS Vaccine

Washington University School of Medicine — EARLY_PHASE1

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Human infection by orthopoxvirus.

8 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

8 recruitingView all trials with filters →
Phase 31 trial
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
Phase 3
Actively Recruiting
· Sites: Boende, La Tshuapa
Phase 23 trials
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
Phase 2
Active
· Sites: Kinshasa; Entebbe +1 more · Age: 250 yrs
An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
Phase 2
Actively Recruiting
PI: Laurens Liesenborghs, MD (Institute of Tropical Medicine) · Sites: Kinshasa · Age: 1845 yrs
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Phase 2
Actively Recruiting
· Sites: Ames, Iowa; Lenexa, Kansas +8 more · Age: 1849 yrs
Phase 11 trial
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
Phase 1
Actively Recruiting
PI: Shuang Li, Master (Henan Infectious Disease Hospital) · Sites: Zhengzhou, Henan · Age: 1899 yrs
N/A1 trial
Clinical and Biological Aspects of the MONKEYPOX Disease
N/A
Actively Recruiting
PI: Fabien Taieb, MD (Institut Pasteur) · Sites: Paris · Age: 1899 yrs
Other1 trial
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Actively Recruiting
PI: Liem Binh Luong Nguyen, Degree medical doctor (Assistance Publique - Hôpitaux de Paris) · Sites: Paris, Paris · Age: 1899 yrs

No specialists are currently listed for Human infection by orthopoxvirus.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Tembexa

Chimerix

Smallpox

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Human infection by orthopoxvirus.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Human infection by orthopoxvirusForum →

No community posts yet. Be the first to share your experience with Human infection by orthopoxvirus.

Start the conversation →

Latest news about Human infection by orthopoxvirus

No recent news articles for Human infection by orthopoxvirus.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific orthopoxvirus is causing my infection, and how severe is this type?,Am I a candidate for antiviral treatment such as tecovirimat (TPOXX)?,How long will I need to isolate, and when am I no longer contagious?,Should my close contacts receive the Jynneos vaccine as post-exposure prevention?,What signs of complications should I watch for at home?,Will I have lasting immunity after this infection, or could I get it again?,What can I do to minimize scarring from the skin lesions?

Common questions about Human infection by orthopoxvirus

What is Human infection by orthopoxvirus?

Human infection by orthopoxvirus refers to diseases caused by viruses in the orthopoxvirus family. This group includes several well-known infections: smallpox (caused by variola virus), monkeypox (now called mpox, caused by monkeypox virus), cowpox, and vaccinia virus infections. Smallpox was one of the deadliest diseases in human history but was officially eradicated in 1980 through a global vaccination campaign. However, other orthopoxvirus infections still occur and are considered rare diseases. These viruses typically affect the skin and cause a characteristic rash that progresses through

How is Human infection by orthopoxvirus inherited?

Human infection by orthopoxvirus follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Human infection by orthopoxvirus?

Yes — 8 recruiting clinical trials are currently listed for Human infection by orthopoxvirus on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

What treatment and support options exist for Human infection by orthopoxvirus?

1 patient support program are currently tracked on UniteRare for Human infection by orthopoxvirus. See the treatments and support programs sections for copay assistance, eligibility, and contact details.